Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Trying to get property 'term_id' of non-object in /var/www/wp-includes/class-wp-query.php on line 3838 Notice: Trying to get property 'name' of non-object in /var/www/wp-includes/class-wp-query.php on line 3840 Notice: Trying to get property 'slug' of non-object in /var/www/wp-includes/class-wp-query.php on line 3842 Notice: Undefined property: WP_Error::$category_parent in /var/www/wp-content/themes/bpi_2014-child/category.php on line 63 Notice: Undefined property: WP_Error::$cat_ID in /var/www/wp-content/themes/bpi_2014-child/category.php on line 67

Catalent pays Erytech $44.5m for NJ cell therapy plant

Catalent has paid Erytech $44.5 million for its 30,900 square-foot facility in New Jersey and will continue to support its lead candidate. Less than a week after the contract development manufacturing organization (CDMO) confirmed a $350 million expansion at its Bloomington, Indiana site, Catalent has acquired a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey from Erytech Pharma for $44.5 million. The facility is located within the University Square Campus Park and has 16 suites that can be used…

Danaher and Sartorius: COVID just one variable affecting bioprocess growth

Comments from J&J have led to questions surrounding the long-term revenues from COVID-19 vaccines. However, the sector is just one area driving bioprocess growth, both Danaher and Sartorius say. While the COVID-19 virus is still virulent in some areas, the rapid development, scale-up, and delivery of vaccines over the past two years has helped bring the world back to some sense of normality. The unprecedented roll-out has resulted in hundreds-of-billions of dollars ending up in the pockets of several vaccine…

Regeneron forks out $250m to buy Checkmate Pharmaceuticals

Regeneron will increase its research efforts in immuno-oncology through the all-cash acquisition of Checkmate Pharmaceuticals. Under the terms of the deal, Regeneron will buy Checkmate at an all-cash price of $10.50 per share of its common stock, which places the proposed acquisition at a total equity value of around $250 million. Checkmate is a clinical-stage biopharmaceutical firm focused on developing technology to treat cancer. Its lead investigational candidate is an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) delivered in…

Seagen building $400m WA manufacturing plant

Seagen will spend between $350 and $400 million over the next three years to construct a greenfield biomanufacturing site in Everett, Washington. Antibody-drug conjugate (ADC) pioneer Seagen (previously Seattle Genetics) will imminently begin constructing a biologics facility in Everett, Washington, close to its existing site in Bothell. The 270,000 square-foot plant is expected to be operational in 2024 and will employ up to 200 workers to produce clinical and commercial products. “In cancer research and development, Seagen must continue to…

Catalent confirms $350m Bloomington expansion

Catalent has announced a multi-year $350 million investment at its plant in Bloomington, Indiana after months of speculation. In February, various publications, including B Square Bulletin, reported that contract development manufacturing organization (CDMO) Catalent is looking to spend $350 million at its Bloomington, Indiana facility with the City of Bloomington supposedly offering the firm millions of dollars in tax breaks. The city council is said to have unanimously voted in favour of the tax breaks two months ago, but a further vote…

Thermo Fisher opens $44m single-use Utah plant

Thermo Fisher says its manufacturing site in Ogden, Utah increases production of single-use bioprocess containers, which are crucial to developing vaccines and therapies. According to Thermo Fisher Scientific, the opening of its 55,000 square-foot single-use technology (SUT) facility in Ogden is part of a long-term $650 million investment the firm announced last March. Thermo claims that the plant provides additional capacity to produce various technology and materials needed for the development of emerging vaccines and breakthrough therapies. The facility will manufacture…

AGC’s big CDMO ambitions

AGC is aiming to make $1.5 billion in sales by 2025 and says it will continue to actively invest in facilities around the world to bolster its CDMO presence. Contract development manufacturing organization (CDMO) AGC says its groups’ life science business forms part of its strategic initiative to aim for sales in the 200-billion-yen ($1.5 billion) range by 2025. “We aim to be the first provider that customer call on when they are looking for a CDMO in various fields…

Ilya aims to strengthen supply chain with Nordic Bioanalysis buy

Ilya Pharma has acquired its long-term partner Nordic Bioanalysis, which it says will help them support the Advanced Therapy Medicinal Product (ATMP) space. The deal, of which no financial details have been disclosed, sees clinical stage immunotherapy firm Ilya Pharma acquire Nordic Bioanalysis (NBAB), which develops pharmaceuticals and biologics, including antibodies and ATMPs. “NBAB mainly provide bioanalytical services for pharmaceuticals and medical devices. The advantages to Ilya Pharma are to de-risk our supply chain for CMC and clinical bioanalytics, the de-risking…

Minimize Risk With Rapid At-Line Concentration Measurement in Downstream Bioprocessing Applications

This webcast features: Paul Mania, Bioanalytics Applications Specialist, Repligen. Traditional UV/Vis spectroscopy uses fixed pathlengths to measure different analytes, such as nucleic acids, proteins, and cells from biological samples. These samples are often limited in volume or highly concentrated, which presents various challenges. The CTech™ SoloVPE® System uses a patented variable pathlength technology (VPT) to accurately measure the targeted concentration of various analytes. The system measures concentrations without being dependent on sample volume or sample concentration, removing any dilution requirements,…

Gilead’s Kite receives US FDA ok for Maryland CAR-T plant

The 20-acre site in Frederick, Maryland will produce CAR-T therapy Yescarta and increase its network capacity by 50%, says Kite. In 2018, Gilead Sciences, fresh from its $11.9 billion acquisition of Kite Pharma, announced plans to expand its manufacturing network with a 275,000 square foot facility in Frederick County, Marland to produce chimeric antigen receptor (CAR) T-cell therapies. Now, the firm has received approval from the US Food and Drug Administration (FDA) to manufacture CAR-T cell therapy Yescarta (axicabtagene ciloleucel), which was…